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Background
The combined use of anticoagulants, antiplatelet agents, and invasive coronary proce-
dures reduces ischemic coronary events but also increases bleeding in patients with 
acute coronary syndromes. We therefore assessed whether fondaparinux would pre-
serve the anti-ischemic benefits of enoxaparin while reducing bleeding.
Methods
We randomly assigned 20,078 patients with acute coronary syndromes to receive 
either fondaparinux (2.5 mg daily) or enoxaparin (1 mg per kilogram of body weight 
twice daily) for a mean of six days and evaluated death, myocardial infarction, or 
refractory ischemia at nine days (the primary outcome); major bleeding; and their 
combination. Patients were followed for up to six months.
Results
The number of patients with primary-outcome events was similar in the two groups 
(579 with fondaparinux [5.8 percent] vs. 573 with enoxaparin [5.7 percent]; hazard 
ratio in the fondaparinux group, 1.01; 95 percent confidence interval, 0.90 to 1.13), 
satisfying the noninferiority criteria. The number of events meeting this combined 
outcome showed a nonsignificant trend toward a lower value in the fondaparinux 
group at 30 days (805 vs. 864, P = 0.13) and at the end of the study (1222 vs. 1308, 
P = 0.06). The rate of major bleeding at nine days was markedly lower with fon da-
parinux than with enoxaparin (217 events [2.2 percent] vs. 412 events [4.1 percent]; 
hazard ratio, 0.52; P<0.001). The composite of the primary outcome and major 
bleeding at nine days favored fondaparinux (737 events [7.3 percent] vs. 905 events 
[9.0 percent]; hazard ratio, 0.81; P<0.001). Fondaparinux was associated with a sig-
nificantly reduced number of deaths at 30 days (295 vs. 352, P = 0.02) and at 180 days 
(574 vs. 638, P = 0.05).
Conclusions
Fondaparinux is similar to enoxaparin in reducing the risk of ischemic events at 
nine days, but it substantially reduces major bleeding and improves long term mor-
tality and morbidity. (ClinicalTrials.gov number, NCT00139815.)
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The combined use of anticoagu-lants,1 antiplatelet agents,2-4 and an invasive strategy5 in high-risk patients with acute 
coronary syndromes reduces ischemic coronary 
events but also increases bleeding. Bleeding may 
increase the risk of death,6 myocardial infarction, 
and stroke. Therefore, future therapies should ei-
ther preserve or enhance benefits without increas-
ing bleeding. Unfractionated heparin and low-
molecular-weight heparins are commonly used in 
patients with acute coronary syndromes, but enoxa-
parin may be modestly superior to unfractionat-
ed heparin in reducing the risk of death or myo-
cardial infarction.7
Fondaparinux (Arixtra, GlaxoSmithKline), a 
synthetic pentasaccharide, selectively binds anti-
thrombin and causes rapid and predictable inhibi-
tion of factor Xa.8 Fondaparinux is more effective 
than enoxaparin in preventing venous thrombo-
sis in patients undergoing orthopedic surgery9 
and is similar in effectiveness to enoxaparin or 
unfractionated heparin in patients with deep-vein 
thrombosis or pulmonary embolism.10,11 Pilot tri-
als involving patients with acute coronary syn-
dromes12,13 and those undergoing percutaneous 
coronary intervention14 suggest that fon da par-
inux may be as effective as enoxaparin or safer 
than unfractionated heparin. The Fifth Organiza-
tion to Assess Strategies in Acute Ischemic Syn-
dromes (OASIS-5) trial compared the efficacy and 
safety of fondaparinux and enoxaparin (Lovenox, 
Sanofi-Aventis) in high-risk patients with unstable 
angina or myocardial infarction without ST-seg-
ment elevation.
Me thods
Study Design
OASIS-5 was a randomized, double-blind, double-
dummy trial in which fondaparinux was compared 
with enoxaparin in patients with unstable angina 
or myocardial infarction without ST-segment el-
evation; 20,078 patients from 576 centers in 41 
countries were included. Details of the protocol 
are reported elsewhere.15 The study was conduct-
ed independently by the steering committee and 
the Population Health Research Institute, McMas-
ter University and Hamilton Health Sciences, 
Hamilton, Ontario, Canada. The study was de-
signed by the steering committee, and the data 
were coordinated and managed independently by 
the Population Health Research Institute, McMas-
ter University and Hamilton Health Sciences. The 
first five members of the writing committee vouch 
for the accuracy and completeness of the data and 
analysis. The study protocol was approved by the 
respective ethics committees and regulatory bod-
ies. The principal investigator had full access to 
the data and drafted the manuscript with input 
from the entire writing committee.
Study Patients
Patients were randomly assigned to a study group 
within 24 hours after the onset of symptoms and 
were eligible if they met at least two of the three 
following criteria: an age of at least 60 years, an 
elevated level of troponin or creatine kinase MB 
isoenzyme, or electrocardiographic changes in-
dicative of ischemia. Patients with contraindi-
cations to low-molecular-weight heparin, recent 
hemorrhagic stroke, indications for anticoagula-
tion other than an acute coronary syndrome, or 
a serum creatinine level of at least 3 mg per deci-
liter (265 μmol per liter) were excluded.
Outcomes
The objective with respect to the primary efficacy 
outcome (death, myocardial infarction, or refrac-
tory ischemia) was to demonstrate the noninferi-
ority of fondaparinux as compared with enoxapa-
rin at nine days. The primary safety objective was 
to determine whether fondaparinux was superior 
to enoxaparin in preventing major bleeding.
Patients were followed for a minimum of 90 
days and a maximum of 180 days. Prespecified 
secondary outcomes included the following: death 
or myocardial infarction; death, myocardial in-
farction, or refractory ischemia; and the individual 
components of these composite outcomes at 30 
days and at the end of the study. Information on 
strokes was also systematically collected. The pri-
mary safety outcome was major bleeding at nine 
days. The balance of benefit and risk was assessed 
on the basis of the combination of the primary 
efficacy and safety outcomes. All events were ad-
judicated in a blinded fashion by a committee. 
Definitions of events have been described sepa-
rately15 and are given in part 1 of the Supplemen-
tary Appendix (available with the full text of this 
article at www.nejm.org).
Study-Drug Administration
After providing written informed consent, patients 
were randomly assigned, by means of a central 
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telephone system, to receive either fonda parinux 
at a dose of 2.5 mg once daily plus placebo enoxa-
parin twice daily by subcutaneous injection or 
enoxaparin at a dose of 1 mg per kilogram of body 
weight twice daily plus placebo fondaparinux 
once daily by subcutaneous injection. In patients 
whose creatinine clearance was below 30 ml per 
minute, the enoxaparin dosage was reduced to 
1 mg per kilogram once daily. Fondaparinux 
could be given until hospital discharge or for up 
to eight days (whichever occurred first), and enox-
aparin was to be given for two to eight days or 
until the patient was in clinically stable condition, 
in an approach consistent with the current ap-
proval for its use in persons with unstable angina 
and myocardial infarction without ST-segment 
elevation. Patients received other standard treat-
ments at the investigators’ discretion.
Cardiac catheterization could be performed at 
any time. If percutaneous coronary intervention 
was to be considered, we recommended use of 
clopidogrel and aspirin at least six hours before 
the procedure. The double-blind arrangement was 
maintained during percutaneous coronary inter-
vention. Patients in the enoxaparin group received 
no additional anticoagulant if they had received 
their subcutaneous enoxaparin injection six hours 
or less before percutaneous coronary intervention; 
if the interval was greater than six hours, the dose 
of weight-adjusted unfractionated heparin was 
0.013 ml per kilogram intravenously if a glyco-
protein IIb/IIIa antagonist was used and was 
0.02 ml per kilogram intravenously if no glycopro-
tein IIb/IIIa antagonist was used. Within six hours 
of the last subcutaneous dose of fondaparinux, 
patients undergoing percutaneous coronary inter-
vention in the absence of a glycoprotein IIb/IIIa 
antagonist received an additional 2.5 mg of intra-
venous fondaparinux; within six hours after the 
last subcutaneous dose of fondaparinux, 2.5 mg 
of intravenous fondaparinux (with a glycopro-
tein IIb/IIIa antagonist) or 5.0 mg of intravenous 
fondaparinux (without a glycoprotein IIb/IIIa an-
tagonist) was administered (part 2 of the Supple-
mentary Appendix).
Statistical Analysis
A sample size of 16,000 was planned on the basis 
of an expected primary-event rate of 8 percent at 
nine days, assuming a one-sided alpha level of 
2.5 percent and a noninferiority margin (delta) 
of 1.185. This noninferiority margin was derived 
Table 1. Characteristics of the Patients and Their Ancillary Treatments.*
Characteristic
Enoxaparin
(N = 10,021)
Fondaparinux
(N = 10,057)
Age — yr 66.6±11.0 66.6±10.8
Male sex — no. (%) 6148 (61.4) 6231 (62.0)
Time from onset of pain to randomization — hr 12.7±6.8 12.7±6.8
Heart rate — beats/min 73.0±13.5 73.0±13.5
Systolic blood pressure — mm Hg 136.3±22.1 136.6±22.7
Diagnosis at study entry — no. (%)
Unstable angina 4517 (45.1) 4581 (45.6)
Suspected myocardial infarction 5502 (54.9) 5474 (54.4)
Medical history — no. (%)
Myocardial infarction 2580 (25.7) 2584 (25.7)
CABG or PCI 1953 (19.5) 2022 (20.1)
Stroke 647 (6.5) 597 (5.9)
Heart failure 1386 (13.8) 1402 (13.9)
Hypertension 6721 (67.1) 6777 (67.4)
Diabetes 2503 (25.0) 2575 (25.6)
Current or former smoker 5473 (54.6) 5440 (54.1)
Any electrocardiographic abnormality — no. (%) 7993 (79.8) 8109 (80.6)
ST-segment depression ≥1 mm — no. (%) 5045 (50.3) 5197 (51.7)
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from a meta-analysis of studies that demonstrat-
ed the benefit of adding unfractionated heparin 
or low-molecular-weight heparin as short-term 
treatment in patients treated with aspirin.1 It 
showed that unfractionated heparin or low-molecu-
lar-weight heparin halves the risk of myocardial 
infarction or death (odds ratio, 0.53; 95 percent 
confidence interval, 0.38 to 0.73) as compared with 
placebo or no treatment during the first week of 
therapy. (The effect of low-molecular-weight hepa-
rin on refractory ischemia, when evaluated, was 
similar to its effect on myocardial infarction.) 
When the inverse of the above result is taken, the 
excess risk due to placebo or no treatment as com-
pared with unfractionated heparin or low-molecu-
lar-weight heparin is 1.89 (95 percent confidence 
interval, 1.37 to 2.63). The noninferiority margin 
of 1.185 was chosen in order to avoid a loss of 
greater than half the lower bound of the 95 per-
cent confidence interval (1.37).16 A blinded review 
of the overall event rate in the first 4000 patients 
indicated that the event rate was lower than ex-
pected. Therefore, the inclusion criteria were mod-
ified so that persons under the age of 60 years 
were required to have both an elevation of bio-
markers and ischemic electrocardiographic chang-
es, and the sample size was increased to 20,000 
patients.
The analyses include all patients who under-
went randomization. The hazard ratio (for fonda-
parinux vs. enoxaparin) and two-sided 95 percent 
confidence interval were calculated with use of a 
Cox proportional-hazards model, with the treat-
ment group as the only covariate. Rates presented 
Table 1. (Continued.)
Characteristic
Enoxaparin
(N = 10,021)
Fondaparinux
(N = 10,057)
Medications at the time of randomization — no. (%)
Aspirin 7829 (78.1) 7815 (77.7)
Clopidogrel or ticlopidine 3160 (31.5) 3134 (31.2)
Unfractionated heparin 1787 (17.8) 1779 (17.7)
Low-molecular-weight heparin 3192 (31.9) 3138 (31.2)
ACE inhibitor or ARB 5131 (51.2) 5135 (51.1)
Beta-blocker 6033 (60.2) 5954 (59.2)
Calcium-channel blocker 2246 (22.4) 2274 (22.6)
Lipid-lowering agent 3862 (38.5) 3843 (38.2)
Medications in the hospital after randomization — no. (%)
Aspirin 9767 (97.5) 9809 (97.5)
Clopidogrel or ticlopidine 6735 (67.2) 6797 (67.6)
Unfractionated heparin 3131 (31.2) 2211 (22.0)
ACE inhibitor or ARB 7630 (76.1) 7535 (74.9)
Beta-blocker 8792 (87.7) 8766 (87.2)
Lipid-lowering agent 7856 (78.4) 7988 (79.4)
Procedures in the hospital — no. (%)
Coronary angiography 6325 (63.1) 6390 (63.5)
PCI 3435 (34.3) 3454 (34.3)
CABG 897 (9.0) 965 (9.6)
Procedures after discharge — no. (%)
Coronary angiography 839 (8.4) 819 (8.1)
PCI 527 (5.3) 516 (5.1)
CABG 560 (5.6) 569 (5.7)
* Plus–minus values are means ±SD. CABG denotes coronary-artery bypass grafting, PCI percutaneous coronary inter-
vention, ACE angiotensin-converting enzyme, and ARB angiotensin-receptor blocker.
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are Kaplan–Meier rates (e.g., the rate of major 
bleeding).
The independent data and safety monitoring 
board monitored outcomes. During the trial, a 
few cases of coronary and catheter-related throm-
bosis were reported during percutaneous coro-
nary intervention. These reports led to concern 
at some sites and on the part of some regulatory 
bodies, and the concern was conveyed to the data 
and safety monitoring board; after repeated re-
view, the members of the board recommended 
continuation of the study. However, the opera-
tions committee (whose members were unaware 
of patients’ treatment assignments) recommend-
ed steps to ensure that the study medications were 
appropriately administered intravenously before 
the procedure and allowed centers to use 200 IU 
of unfractionated heparin to flush the catheters.
All reported events not refuted by the adjudi-
cation committee were included. Vital status was 
ascertained for 20,066 of the 20,078 randomly as-
signed patients (99.9 percent); 7 patients in the 
fon da parinux group and 5 in the enoxaparin group 
were lost to follow-up by day 9.
R esult s
The characteristics of the patients and their an-
cillary therapies are listed in Table 1. Seventy per-
cent of the patients were enrolled by hospitals 
with a cardiac-catheterization laboratory.
Efficacy
The primary efficacy outcome (death, myocardial 
infarction, or refractory ischemia at nine days) 
occurred in 579 of the 10,057 patients randomly 
assigned to receive fondaparinux (5.8 percent), as 
compared with 573 of the 10,021 patients as-
signed to receive enoxaparin (5.7 percent) (haz-
ard ratio, 1.01; 95 percent confidence interval, 
0.90 to 1.13) (Fig. 1A and Table 2). This result 
confirms the noninferiority of fondaparinux as 
compared with enoxaparin because the upper 
confidence limit is well below the prespecified 
boundary of 1.185 (P = 0.007 for noninferiority). 
The rates of the main secondary outcome (death 
or myocardial infarction) were also similar, at 
4.1 percent in the fondaparinux group and 4.1 
percent in the enoxaparin group (hazard ratio, 
0.99; 95 percent confidence interval, 0.86 to 1.13); 
again, the upper confidence limit is below the 
noninferiority boundary (P = 0.005).
At 30 days, there was a trend toward a lower 
rate of death, myocardial infarction, or refractory 
ischemia with fondaparinux than with enoxapa-
rin (8.0 percent vs. 8.6 percent; hazard ratio, 0.93; 
95 percent confidence interval, 0.84 to 1.02) and 
of the composite of death or myocardial infarc-
tion (6.2 percent vs. 6.8 percent; hazard ratio, 
0.90; 95 percent confidence interval, 0.81 to 1.01) 
(Table 2). These differences were due to a signifi-
cant reduction in mortality with fondaparinux 
(2.9 percent, vs. 3.5 percent with enoxaparin; 
hazard ratio, 0.83; 95 percent confidence inter-
val, 0.71 to 0.97; P = 0.02). The above differences 
persisted until the end of follow-up: the rates of 
death, myocardial infarction, or refractory ische-
mia were 12.3 percent in the fondaparinux group 
and 13.2 percent in the enoxaparin group (haz-
ard ratio, 0.93; 95 percent confidence interval, 
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Figure 1. Cumulative Risks of Death, Myocardial Infarction, or Refractory 
Ischemia (Panel A) and of Major Bleeding (Panel B) through Day 9.
The hazard ratios are for the fondaparinux group as compared with the 
enoxaparin group. CI denotes confidence interval.
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0.86 to 1.00; P = 0.06); the rates of death or myo-
cardial infarction were 10.5 percent and 11.4 per-
cent, respectively (hazard ratio, 0.92; 95 percent 
confidence interval, 0.84 to 1.00; P = 0.05); and 
the rates of death were 5.8 percent and 6.5 per-
cent, respectively (hazard ratio, 0.89; 95 percent 
confidence interval, 0.80 to 1.00; P = 0.05) (Fig. 
2 and Table 2, and Fig. 1 of the Supplementary 
Appendix).
Bleeding
The rate of major bleeding at nine days was sub-
stantially lower in the fondaparinux group than 
in the enoxaparin group (2.2 percent vs. 4.1 per-
Table 2. Main Efficacy and Safety Outcomes.*
Time and Outcome
Enoxaparin
(N = 10,021)
Fondaparinux
(N = 10,057)
Hazard Ratio 
(95% CI)
P Value 
for Superiority
P Value for 
Noninferiority
no. of events (% of patients)
9 Days
Death, MI, or refractory ischemia 573 (5.7) 579 (5.8) 1.01 (0.90–1.13) NA 0.007
Death or MI† 412 (4.1) 409 (4.1) 0.99 (0.86–1.13) NA 0.005
Death 186 (1.9) 177 (1.8) 0.95 (0.77–1.17) NA
MI 264 (2.7) 263 (2.6) 0.99 (0.84–1.18) NA
Refractory ischemia 188 (1.9) 194 (1.9) 1.03 (0.84–1.26) NA
Stroke 45 (0.5) 37 (0.4) 0.82 (0.53–1.27) NA
Major bleeding 412 (4.1) 217 (2.2) 0.52 (0.44–0.61) <0.001
Death, MI, refractory ischemia, or major 
bleeding
905 (9.0) 737 (7.3) 0.81 (0.73–0.89) <0.001
Death, MI, or stroke 446 (4.5) 435 (4.3) 0.97 (0.85–1.11) 0.67
30 Days
Death, MI, or refractory ischemia 864 (8.6) 805 (8.0) 0.93 (0.84–1.02) 0.13
Death or MI 682 (6.8) 619 (6.2) 0.90 (0.81–1.01) 0.07
Death 352 (3.5) 295 (2.9) 0.83 (0.71–0.97) 0.02
MI 411 (4.1) 387 (3.9) 0.94 (0.82–1.08)
Refractory ischemia 222 (2.2) 220 (2.2) 0.99 (0.82–1.19)
Stroke 95 (1.0) 74 (0.7) 0.77 (0.57–1.05)
Major bleeding 494 (5.0) 313 (3.1) 0.62 (0.54–0.72) <0.001
Death, MI, refractory ischemia, or major 
bleeding
1238 (12.4) 1025 (10.2) 0.82 (0.75–0.89) <0.001
Death, MI, or stroke 752 (7.5) 671 (6.7) 0.89 (0.80–0.98) 0.02
180 Days
Death, MI, or refractory ischemia 1308 (13.2) 1222 (12.3) 0.93 (0.86–1.00) 0.06
Death or MI 1127 (11.4) 1042 (10.5) 0.92 (0.84–1.00) 0.05
Death 638 (6.5) 574 (5.8) 0.89 (0.80–1.00) 0.05
MI 635 (6.6) 606 (6.3) 0.95 (0.85–1.06)
Refractory ischemia 238 (2.4) 231 (2.3) 0.97 (0.81–1.16)
Stroke 161 (1.7) 127 (1.3) 0.78 (0.62–0.99) 0.04
Major bleeding 569 (5.8) 417 (4.3) 0.72 (0.64–0.82) <0.001
Death, MI, refractory ischemia, or major 
bleeding
1698 (17.1) 1493 (15.0) 0.86 (0.81–0.93) <0.001
Death, MI, or stroke 1234 (12.5) 1113 (11.3) 0.89 (0.82–0.97) 0.007
* Strokes were prospectively documented and centrally adjudicated. The composite of death, myocardial infarction (MI), or stroke was not a 
prespecified outcome. CI denotes confidence interval, and NA not applicable.
† The noninferiority criterion was based on the primary outcome, but the secondary outcome of death or MI also satisfied this criterion.
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cent; hazard ratio, 0.52; 95 percent confidence 
interval, 0.44 to 0.61; P<0.001) (Fig. 1B and Ta-
ble 2). This difference persisted during long-term 
follow-up. Fondaparinux was associated with a 
significant reduction in the number of patients 
with fatal bleeding (7, vs. 22 in the enoxaparin 
group; P = 0.005) and severe bleeding according 
to the Thrombolysis in Myocardial Infarction cri-
teria17 (70, vs. 126; hazard ratio, 0.55; 95 percent 
confidence interval, 0.41 to 0.74; P<0.001). Larger 
differences in the rates of minor bleeding were 
observed (1.1 percent in the fondaparinux group 
vs. 3.2 percent in the enoxaparin group), so that 
the rates of total bleeding were substantially low-
er with fondaparinux than with enoxaparin (3.3 
percent vs. 7.3 percent; hazard ratio, 0.44; 95 per-
cent confidence interval, 0.39 to 0.50). Although 
the number of patients with intracranial bleed-
ing was the same — 7 — in each group, the num-
bers of patients with major bleeding requiring 
surgical intervention (41 vs. 77), retroperitoneal 
bleeding (9 vs. 37), transfusions (164 vs. 287), 
and bleeding associated with death at the end of 
the study (38 vs. 79) were significantly lower with 
fondaparinux than with enoxaparin (P<0.001 for 
all comparisons). The rate of major bleeding was 
significantly lower with fondaparinux than with 
enoxaparin among patients with a creatinine 
clearance below 30 ml per minute (6 of 265 pa-
tients [2.4 percent] had major bleeding vs. 26 of 
270 [9.9 percent], P = 0.001) or a creatinine clear-
ance of at least 30 ml per minute (211 of 9743 [2.2 
percent] vs. 384 of 9699 [4.0 percent], P<0.001).
Regardless of treatment, patients who had 
major bleeding during hospitalization had sig-
nificantly higher rates of death (13.2 percent vs. 
2.8 percent), reinfarction (11.9 percent vs. 3.6 per-
cent), or stroke (3.5 percent vs. 0.7 percent) at 30 
days (P<0.001) and at 180 days (data not shown) 
than patients without major or minor bleeding. 
The mortality rate among those who had minor 
bleeding was also higher at 30 days than among 
those with no bleeding episodes (6.9 percent vs. 
2.8 percent). These higher event rates associated 
with bleeding persisted after adjustment for vari-
ous clinical characteristics associated with bleed-
ing. In analyzing the difference of 64 between the 
groups in the number of deaths at the end of the 
study, we found that 41 fewer patients in the fon-
daparinux group than in the enoxaparin group 
died after major bleeding (38 vs. 79) and that 20 
fewer patients in the fondaparinux group died 
after minor bleeding (13 vs. 33). Therefore, almost 
the entire difference in mortality between the 
groups at the end of the study could be attributed 
to the lower rate of bleeding with fondaparinux.
Balance of Benefit and Risk
The composite of death, myocardial infarction, 
refractory ischemia, or major bleeding occurred 
in 7.3 percent of the patients in the fondaparinux 
group, as compared with 9.0 percent of the pa-
tients in the enoxaparin group (hazard ratio, 
0.81; 95 percent confidence interval, 0.73 to 0.89; 
P<0.001) at nine days (Table 2, and Fig. 2 and 3 of 
the Supplementary Appendix). This difference per-
sisted until the end of the study.
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Other Efficacy Outcomes
There was a significant reduction in the rate of 
stroke with fondaparinux (1.3 percent, vs. 1.7 per-
cent with enoxaparin; P = 0.04) at the end of the 
study. The composite outcome of death, myocar-
dial infarction, or stroke was also significantly re-
duced with fondaparinux (11.3 percent vs. 12.5 
percent; hazard ratio, 0.89; 95 percent confidence 
interval, 0.82 to 0.97; P = 0.007) (Table 2 and Fig. 2).
Subgroup Analyses
The benefits and risks were consistent among 
most subgroups. Consequently, the reduction in 
the composite outcome of death, myocardial in-
farction, refractory ischemia, or major bleeding 
with fondaparinux as compared with enoxaparin 
was observed in all the subgroups. The rates of 
bleeding were consistently lower with fonda-
parinux, regardless of whether unfractionated hep-
arin was administered before randomization (2.0 
percent in the fondaparinux group vs. 4.0 percent 
in the enoxaparin group among those who did 
not receive unfractionated heparin [P<0.001] and 
3.0 percent vs. 5.0 percent among those who did 
receive unfractionated heparin [P = 0.003]) (Fig. 3) 
or after randomization. The rates of bleeding were 
also lower with fondaparinux regardless of the 
baseline creatinine level and regardless of the pres-
ence or absence of a catheterization laboratory at 
the center.
Revascularization Procedures
The proportions of patients undergoing percuta-
neous coronary intervention (39.5 percent in the 
fondaparinux group and 39.5 percent in the enoxa-
parin group) or coronary-artery bypass grafting 
(15.3 percent and 14.5 percent, respectively) were 
similar in the two groups. Among patients under-
going percutaneous coronary intervention in the 
hospital, the rates of the combination of death, 
myocardial infarction, and refractory ischemia 
were similar at 9 days (9.3 percent in the fonda-
parinux group and 8.6 percent in the enoxaparin 
group), at 30 days (10.4 percent and 9.6 percent, 
respectively), and at the end of the study (12.9 per-
cent and 12.3 percent, respectively). At 30 days, 
the rates of death (2.0 percent with fondaparinux 
and 2.1 percent with enoxaparin) (Table 3) and of 
death or myocardial infarction (7.1 percent and 
6.8 percent) were similar in the two groups. The 
rates of coronary complications during the pro-
cedure also were similar. The rates of clinical out-
comes and procedural complications were simi-
lar in the two groups both before and after the 
amendment recommended by the operations com-
mittee.
The rate of major bleeding 48 hours after the 
procedure was significantly lower with fonda-
parinux than with enoxaparin (1.6 percent vs. 
3.6 percent before the amendment and 1.4 per-
cent vs. 3.4 percent after the amendment; P<0.001 
for both comparisons). Bleeding was significantly 
reduced with fondaparinux among patients re-
ceiving additional heparin (P<0.001) and those 
not receiving it (P<0.001). There was an increase 
in the rate of guiding-catheter thrombus for-
mation with fondaparinux (29 episodes [0.9 per-
cent], vs. 8 episodes with enoxaparin [0.3 per-
cent]) — a difference that was observed both 
before (1.2 percent vs. 0.3 percent) and after 
(0.7 percent vs. 0.2 percent) the amendment. The 
rates of other complications of percutaneous 
coronary intervention were significantly lower 
with fondaparinux than with enoxaparin (pseu-
doaneurysms requiring closure, 1.0 percent vs. 
1.6 percent [P = 0.04]; large hematoma, 1.6 per-
cent vs. 4.4 percent [P<0.001]; and complications 
involving the vascular access site, 3.3 percent vs. 
8.1 percent [P<0.001]). The rate of death, myocar-
dial infarction, stroke, major bleeding, or any 
procedural complication at nine days was 16.6 
percent with fondaparinux, as compared with 
20.6 percent with enoxaparin (relative risk, 0.81; 
95 percent confidence interval, 0.73 to 0.90; 
P<0.001) (Table 3).
Adherence
At least one dose of allocated study drug was ad-
ministered to 99.2 percent of the patients in the 
fondaparinux group and 99.4 percent of those in 
the enoxaparin group. The mean durations of 
treatment were similar in the two groups (5.4 and 
5.2 days, respectively).
Discussion
Our study has three important findings. First, in 
the short term, fondaparinux and enoxaparin 
have similar efficacy. Second, as compared with 
enoxaparin, fondaparinux substantially reduces 
bleeding. Third, the reduced bleeding that ac-
companies the use of fondaparinux is associated 
with lower long-term mortality and morbidity.
Fondaparinux was statistically noninferior to 
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Figure 3. Results of Subgroup Analyses of Efficacy (the Composite of Death, Myocardial Infarction, or Refractory Ischemia) (Panel A) 
and Safety (Major Bleeding) (Panel B) at Nine Days.
Hazard ratios are shown with 95 percent confidence intervals. The sizes of the symbols are in proportion to the number of patients 
in the comparison. The median value for creatinine was 88 mg per deciliter (1.04 mmol per liter). Data are missing for some patients.
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enoxaparin with respect to the primary compos-
ite outcome of death, myocardial infarction, or 
refractory ischemia at nine days. Analysis of the 
rates of each component of the composite out-
come, including death or myocardial infarction, 
yielded similar results. When we examined the 
30-day outcomes, however, there was a strong 
trend toward superiority with fondaparinux. 
Fondaparinux significantly reduced the rate of 
death as well as the rate of the composite of 
death, myocardial infarction, and stroke at these 
times.
Table 3. Treatments, Complications, and Outcomes among Patients Undergoing Percutaneous Coronary Intervention 
(PCI) within the First Eight Days after Randomization.*
Variable
Enoxaparin
(N = 3104)
Fondaparinux
(N = 3135)
Relative Risk
(95% CI) P Value
no. of events (% of patients)
Concomitant antithrombotic drugs 
Unfractionated heparin 1724 (55.5) 651 (20.8)
Glycoprotein IIb/IIIa inhibitor 1273 (41.0) 1308 (41.7)
Thienopyridines 2317 (74.6) 2348 (74.9)
Complications involving the vascular access site
Any complication 251 (8.1) 103 (3.3) 0.41 (0.33–0.51) <0.001
Pseudoaneurysm 49 (1.6) 31 (1.0) 0.63 (0.40–0.98)
Large hematoma 138 (4.4) 50 (1.6) 0.36 (0.26–0.49)
PCI-related coronary complication†
Any complication 268 (8.6) 299 (9.5) 1.11 (0.94–1.29) 0.21
Abrupt closure, new thrombus with reduced 
flow, dissection, or no reflow
161 (5.2) 188 (6.0) 1.16 (0.94–1.42)
Catheter-related thrombus not resulting in 
clinical complications‡
3 (0.1) 9 (0.3) 2.99 (0.81–11.04) 0.08
All catheter-related thrombi‡ 8 (0.4) 29 (0.9) 3.59 (1.64–7.84) 0.001
Hazard Ratio (95% CI)
Clinical events at 9 days
Death 38 (1.2) 37 (1.2) 0.96 (0.62–1.51)
MI 154 (5.0) 161 (5.1) 1.04 (0.84–1.28)
Stroke 13 (0.4) 13 (0.4) 0.99 (0.46–2.13)
Major bleeding 158 (5.1) 72 (2.3) 0.45 (0.34–0.59)
Death, MI, or stroke 190 (6.1) 198 (6.3) 1.03 (0.87–1.25)
Death, MI, stroke, or major bleeding 321 (10.3) 255 (8.2) 0.79 (0.67–0.92) 0.003
Any procedural complication, major bleeding, 
death, MI, or stroke at 9 days
638 (20.6) 521 (16.6) 0.81 (0.73–0.90) <0.001
Clinical events at 30 days
Death 65 (2.1) 62 (2.0) 0.94 (0.67–1.33)
MI 169 (5.4) 179 (5.7) 1.05 (0.86–1.29)
Stroke 22 (0.7) 18 (0.6) 0.81 (0.44–1.51)
Major bleeding 169 (5.4) 87 (2.8) 0.51 (0.40–0.66)
Death, MI, or stroke 228 (7.3) 231 (7.4) 1.00 (0.84–1.20)
Death, MI, stroke, or major bleeding 364 (11.7) 297 (9.5) 0.81 (0.70–0.93) 0.004
* CI denotes confidence interval, and MI myocardial infarction.
† PCI-related coronary complications included death, MI, or stroke at 48 hours as well as the events listed.
‡ All cases of catheter-related thrombi were centrally adjudicated.
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Major bleeding was reduced by about half and 
minor bleeding by about two thirds with fonda-
parinux. The prespecified analysis combining ef-
ficacy and safety was significantly reduced with 
fondaparinux. Bleeding increased the long-term 
risk of death,18 and differences in bleeding ap-
peared to account for the reduction in the long-
term risk of death with fondaparinux. In addition, 
there were significantly fewer strokes with fonda-
parinux than with enoxaparin. Therefore, the net 
clinical benefit is clearly in favor of fondaparinux. 
The reduction in bleeding was consistently ob-
served for episodes that were fatal, serious, or 
minor. The last category included cases in which 
one unit of blood was transfused or study medi-
cations were stopped. Several previous studies 
have found increased rates of death, stroke, and 
myocardial infarction among persons who had a 
bleeding episode.6,18 In the context of current 
treatments for acute coronary syndromes, the rate 
of major bleeding with enoxaparin is higher than 
the rate of death, myocardial infarction, or refrac-
tory ischemia when each outcome is considered 
separately. Therefore, although the contemporary 
practice of using multiple antiplatelet agents,19 a 
thrombin inhibitor, and an invasive strategy may 
have substantially reduced ischemic events, it has 
also increased bleeding.
Fondaparinux is an alternative to enoxaparin 
because it preserves short-term efficacy but sub-
stantially reduces bleeding. This effect translates 
into lower long-term rates of death, myocardial 
infarction, and stroke. The reasons for increased 
bleeding with enoxaparin are unclear but may 
relate to the intrinsic properties associated with 
inhibiting thrombin (trials of direct thrombin 
inhibitors have shown increased bleeding when 
those agents are compared with unfractionated 
heparin)20; in addition, it is possible that the cur-
rently recommended doses of enoxaparin may be 
too high (although the efficacy of lower doses 
has not been proven). The rates of bleeding with 
enoxaparin in OASIS-5 were lower than those in 
previous trials.7,21 The mechanisms underlying 
the increased mortality or morbidity associated 
with bleeding are unclear but may relate to re-
bound ischemic events due to activation of clot-
ting, cessation of antithrombotic therapies after 
a bleeding event, or adverse effects of hypoten-
sion or transfusions. Given that major bleeding 
has serious long-term consequences, treatment 
strategies that reduce the risk of bleeding while 
maintaining or enhancing the benefits of reduced 
ischemic events are required. Fondaparinux is an 
important step toward such a strategy.
The reduced rates of bleeding with fonda-
parinux were consistently observed in all the sub-
groups examined. The recent Superior Yield of the 
New Strategy of Enoxaparin, Revascularization, 
and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) 
trial21 found a higher rate of bleeding among 
patients who received additional unfractionated 
heparin with enoxaparin than among those who 
received enoxaparin alone. However, this result 
cannot explain the reduced risk of bleeding as-
sociated with fondaparinux in our trial, since less 
bleeding was observed even among patients who 
did not receive any unfractionated heparin. The 
regimen of enoxaparin that we used (with a re-
duced dose in cases of severe renal impairment) 
is the standard currently recommended,19 and 
an excess of bleeding with enoxaparin was seen 
among patients with low or elevated creatinine 
clearances.
In summary, fondaparinux at a dose of 2.5 mg 
daily is similar to enoxaparin in the short term 
in preventing ischemic events among patients 
with acute coronary syndromes without ST-seg-
ment elevation, but it is associated with substan-
tially less bleeding — an effect that translates 
into lower long-term mortality and morbidity. 
Therefore, fondaparinux is an attractive option as 
an anticoagulant in the short-term care of patients 
with acute coronary syndromes.
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